Get the Stockscreener App
93.61
0.06%
0.06
After Hours:
93.49
-0.12
-0.13%
Boston Scientific Corp stock is traded at $93.61, with a volume of 9.60M.
It is up +0.06% in the last 24 hours and down -2.55% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$93.55
Open:
$93.23
24h Volume:
9.60M
Relative Volume:
0.99
Market Cap:
$138.83B
Revenue:
$19.35B
Net Income/Loss:
$2.78B
P/E Ratio:
50.07
EPS:
1.8696
Net Cash Flow:
$3.82B
1W Performance:
+2.64%
1M Performance:
-2.55%
6M Performance:
-11.81%
1Y Performance:
-8.47%
1-Day Range:
$92.70
$93.92
1-Week Range:
$90.44
$94.75
52-Week Range:
$85.98
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific completes Nalu Medical acquisition - MassDevice
Transcatheter Embolization and Occlusion Devices Market Size to be Valued at USD 11.53 Billion by 2033, Driven by Rising Oncology and Neurovascular Interventions – SNS Insider - GlobeNewswire Inc.
Boston Scientific (BSX) stock ticks higher again — what to watch before Tuesday’s trade - TechStock²
Boston Scientific to acquire Alameda-based Penumbra for $14.5 billion - MSN
Boston Scientific (BSX) Sees Surge in Call Options Activity - GuruFocus
Boston Scientific stock rises as Evercore taps BSX for a tactical list ahead of earnings - TechStock²
Lbp Am Sa Increases Position in Boston Scientific Corporation $BSX - MarketBeat
Evercore ISI reiterates Outperform rating on Boston Scientific stock - Investing.com
Hospitals are embracing pulsed field ablation. Here’s why - Modern Healthcare News
Algebris UK Ltd. Invests $1.77 Million in Boston Scientific Corporation $BSX - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Has $72.29 Million Stake in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific stock navigates a cautious upswing as Wall Street leans bullish - AD HOC NEWS
UniSuper Management Pty Ltd Boosts Holdings in Boston Scientific Corporation $BSX - MarketBeat
What Does the Market Think About Boston Scientific Corp? - Sahm
Oppenheimer Questions Valuation of Boston Scientific's $14.5 Billion Penumbra Deal - Finviz
Oppenheimer Questions Valuation of Boston Scientific’s $14.5 Billion Penumbra Deal - Yahoo Finance
Boston Scientific stock price: BSX ends higher as Fitch turns credit outlook positive ahead of key catalysts - TechStock²
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Boston Scientific ratings affirmed by Fitch, outlook positive - Investing.com
Boston Scientific stock (BSX) climbs as heart-rhythm rivalry and deal risk stay in play - TechStock²
Teacher Retirement System of Texas Has $77.67 Million Stake in Boston Scientific Corporation $BSX - MarketBeat
iA Global Asset Management Inc. Acquires 31,717 Shares of Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corporation (NYSE:BSX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Oppenheimer Questions $14.5B Penumbra Deal Valuation Despite Boston Scientific's (BSX) Mew Market Dominance - Finviz
A Closer Look at Boston Scientific's Options Market Dynamics - Benzinga
Boston Scientific announces agreement to acquire Penumbra, Inc. - Quantisnow
Boston Scientific Corporation (NYSE:BSX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Boston Sci secures CE mark for Embold system - BioWorld MedTech
Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface - Benzinga
Boston Scientific (BSX) to acquire Penumbra in $14.5B neurovascular push - Stock Titan
Universal Beteiligungs und Servicegesellschaft mbH Reduces Holdings in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific (BSX): Company Profile, Stock Price, News, Rankings - Fortune
Boston Scientific to acquire Penumbra (NYSE: PEN) in $14.5B deal - Stock Titan
Investors Purchase Large Volume of Call Options on Boston Scientific (NYSE:BSX) - MarketBeat
Boston Scientific stock rises as BSX teases new pain-therapy data while FDA stent alert hangs over shares - TechStock²
Boston Scientific has a potentially serious Axios stent recall - MassDevice
Boston Scientific stock rating reiterated at Outperform by Mizuho - Investing.com
Boston Scientific recalls stent over issue linked to 3 deaths - MedTech Dive
3 takeaways from Boston Scientific’s $14.5B Penumbra deal - MedTech Dive
Boston Scientific to Acquire Alameda-Based Penumbra for $14.5 Billion - alamedapost.com
Analysts Are Bullish on These Healthcare Stocks: Henry Schein (HSIC), Boston Scientific (BSX) - The Globe and Mail
Canaccord Genuity downgrades Penumbra stock to Hold after Boston Scientific deal - Investing.com
Penumbra shares soar pre-market — what is the Boston Scientific agreement? - MSN
Boston Scientific to Acquire Penumbra - Diagnostic and Interventional Cardiology
Boston Scientific’s Strategic Acquisition Tests Investor Resolve - AD HOC NEWS
Allstate Corp Has $5.31 Million Stake in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific to acquire Penumbra, expanding cardiovascular portfolio - Today's Medical Developments
Penumbra Shares Soar Pre-MarketWhat Is The Boston Scientific Agreement? - Menafn
UnitedHealth Stock Slips Amid Medicare Investigation; Boston Scientific to Acquire Penumbra for $14.5B - Intellectia AI
Is Boston Scientific Corporation (NYSE:BSX) Worth US$88.1 Based On Its Intrinsic Value? - Yahoo Finance
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):